Mednet Logo
HomeQuestion

How would you manage a CLL patient with Richters transformation that is resistant to R-CHOP with transfusion dependent cytopenias and a marrow demonstrating significant involvement by DLBCL and CLL?

2 Answers
Mednet Member
Mednet Member
Medical Oncology · Mayo Clinic Jacksonville

Very hard situation. Probably this patient has received BTKi and venetoclax based therapies already. These cases are difficult to treat. There are no standard therapies.

Ideally, I try to take them to CAR-T therapy. The challenge is how to collect due to significant cytopenias due to extensive marr...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Medical Oncology · Cleveland Clinic

Agree that this is very difficult. Combination of venetoclax + Btk inhibitor is safe and can be active in this situation. I also like the idea of anti-CD20 monoclonal antibody.


I am not aware of any data on the use of polatuzumab vedotin in Richter's, but this would be an option (+rituximab) if mos...

Register or Sign In to see full answer

How would you manage a CLL patient with Richters transformation that is resistant to R-CHOP with transfusion dependent cytopenias and a marrow demonstrating significant involvement by DLBCL and CLL? | Mednet